MATERIAL SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Material Name: Atarax® (Hydroxyzine hydrochloride) tablets

Trade Name: Atarax (R)
Chemical Family: Mixture
Intended Use: Pharmaceutical product used for sedative, anxiolytic, Antipruritic.

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alginic acid</td>
<td>9005-32-7</td>
<td>232-680-1</td>
<td>*</td>
</tr>
<tr>
<td>Hydroxyzine hydrochloride</td>
<td>2192-20-3</td>
<td>218-586-3</td>
<td>12.5 - 32.6</td>
</tr>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium phosphate dibasic, anhydrous</td>
<td>7757-93-9</td>
<td>231-826-1</td>
<td>*</td>
</tr>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
<td>200-659-2</td>
<td>*</td>
</tr>
<tr>
<td>Polyethylene glycol</td>
<td>25322-68-3</td>
<td>Not listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Tablets, varying in color depending on strength
Signal Word: WARNING

Statement of Hazard: May be harmful if swallowed.
Possible risk of harm to the unborn child.
May cause central nervous system effects.

Additional Hazard Information:
Short Term: Accidental ingestion may cause effects similar to those seen in clinical use.
Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects: The most commonly reported adverse effects seen with the use of hydroxyzine include drowsiness, somnolence, headache, weakness, depression, and irritability.

EU Indication of danger: Harmful
Toxic to Reproduction; Category 3
EU Hazard Symbols:

EU Risk Phrases:
R22 - Harmful if swallowed.
R63 - Possible risk of harm to the unborn child.

Note:
This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. Get medical attention.

Skin Contact: Remove clothing and wash affected skin with soap and water. If irritation occurs or persists, get medical attention. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder.

Ingestion: Get medical attention immediately. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.

Fire Fighting Procedures: Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes.

Storage Conditions: Keep container tightly closed when not in use. Store out of direct sunlight in a well ventilated area at room temperature.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hydroxyzine hydrochloride

Pfizer OEL TWA-8 Hr: 0.3 mg/m³

Starch

OSHA - Final PELS - TWAs:
= 15 mg/m³ TWA total
= 5 mg/m³ TWA

ACGIH Threshold Limit Value (TWA)
= 10 mg/m³ TWA

Australia TWA
= 10 mg/m³ TWA

Magnesium stearate

ACGIH Threshold Limit Value (TWA)
= 10 mg/m³ TWA except stearates of toxic metals

Australia TWA
= 10 mg/m³ TWA

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with large quantities.

Eyes: Not required under normal conditions of use. Glasses or goggles are recommended if eye contact is possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with large quantities.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Tablet

Color: Red, yellow, orange, green

Odor: Odorless

Molecular Formula: Mixture

Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable

Conditions to Avoid: None known

Incompatible Materials: Strong oxidizers

Hazardous Decomposition Products: No data available
Polymerization: Will not occur

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Alginic acid
Rat Oral LD50 > 5 g/kg

Lactose
Rat Oral LD50 > 10 g/kg

Magnesium stearate
Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Starch
Mouse IP LD50 6600 mg/kg

Hydroxyzine hydrochloride
Rat Oral LD50 840 mg/kg
Mouse IP LD50 81 mg/kg
Rat IP LD50 160 mg/kg
Mouse IV LD50 137 mg/kg
Rat IV LD50 45 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Polyethylene glycol
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Hydroxyzine hydrochloride
Reproductive & Fertility Rat Oral 400 mg/kg LOAEL Developmental toxicity, Reproductive toxicity
Reproductive Effects
Teratogenicity
Hydroxyzine when administered to the pregnant mouse, rat, and rabbit, induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Hydroxyzine has been associated with teratogenesis in beagle puppies. In pregnant monkeys (one per dose group), oral doses of 6, 8, and 12 mg/kg resulted in abortion in all three pregnancies. However, dosing at 5 or 10 mg/kg did not produce abortions, nor were any gross malformations seen in offspring.

Mutagenicity
No data available

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

At increase risk from exposure: Individuals with a history of hypersensitivity to this material or other materials in its chemical class may be susceptible to the toxicity of overexposure. Individuals taking central nervous system depressants (alcohol, hypnotics, narcotics, barbiturates) should avoid exposure to this material.
12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Harmful
Toxic to Reproduction; Category 3

EU Risk Phrases:
R22 - Harmful if swallowed.
R63 - Possible risk of harm to the unborn child.

EU Safety Phrases:
S22 - Do not breathe dust.
S36 - Wear suitable protective clothing.
S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:
WARNING
May be harmful if swallowed.
Possible risk of harm to the unborn child.
May cause central nervous system effects.

Canada - WHMIS: Classifications

WHMIS hazard class:
Class D, Division 2, Subdivision A

Alginic acid
16. OTHER INFORMATION

<table>
<thead>
<tr>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>EU EINECS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>Hydroxyzine hydrochloride</td>
<td>232-680-1</td>
</tr>
<tr>
<td>Calcium phosphate dibasic, anhydrous</td>
<td>231-826-1</td>
</tr>
<tr>
<td>Lactose</td>
<td>232-679-6</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>200-559-2</td>
</tr>
<tr>
<td>Polyethylene glycol</td>
<td>209-150-3</td>
</tr>
</tbody>
</table>

Reasons for Revision: Updated Section 3 - Hazard Identification. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet